Renin-angiotensin sytem blockers
Phase 3Small molecule
Renin-angiotensin sytem blockers is one of 30 small molecule programs targeting Nephropathy. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
29
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
35 competitors in Nephropathy
#DrugCompanyPhaseTrials
1Alka-Seltzer
AAbbott
Approved
Rocaltrol
Jazz PharmaceuticalsApproved
Theo-Dur
PfizerApproved
Rituxan
RocheApproved
Crestor
AstraZenecaApproved
Micardis
Boehringer IngelheimApproved
Zocor
OOrganon and Co
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Nitrostat
VViatris Specialty LLC
Approved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- FFondazione Schena